1. Home
  2. HYI vs MSLE Comparison

HYI vs MSLE Comparison

Compare HYI & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset High Yield Defined Opportunity Fund Inc.

HYI

Western Asset High Yield Defined Opportunity Fund Inc.

HOLD

Current Price

$10.16

Market Cap

135.2M

Sector

Finance

ML Signal

HOLD

Logo Satellos Bioscience Inc. Common Stock

MSLE

Satellos Bioscience Inc. Common Stock

N/A

Current Price

$9.39

Market Cap

154.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
HYI
MSLE
Founded
2010
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
135.2M
154.6M
IPO Year
2010
2007

Fundamental Metrics

Financial Performance
Metric
HYI
MSLE
Price
$10.16
$9.39
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
61.4K
24.5K
Earning Date
01-01-0001
N/A
Dividend Yield
9.59%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.10
$5.44
52 Week High
$12.12
$13.39

Technical Indicators

Market Signals
Indicator
HYI
MSLE
Relative Strength Index (RSI) 30.95 47.80
Support Level N/A $8.88
Resistance Level $10.66 $9.75
Average True Range (ATR) 0.09 0.52
MACD -0.01 -0.01
Stochastic Oscillator 36.75 34.62

Price Performance

Historical Comparison
HYI
MSLE

About HYI Western Asset High Yield Defined Opportunity Fund Inc.

Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.

About MSLE Satellos Bioscience Inc. Common Stock

Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.

Share on Social Networks: